Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial-Reference-Cited by-同舟云学术

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Published:2011-11 Issue:9805 Volume:378 Page:1779-1787
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kappos Ludwig,Li David,Calabresi Peter A,O'Connor Paul,Bar-Or Amit,Barkhof Frederik,Yin Ming,Leppert David,Glanzman Robert,Tinbergen Jeroen,Hauser Stephen L

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Autoimmune inflammation from the Th17 perspective;Furuzawa-Carballeda;Autoimmun Rev,2007

2. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage;Nessler;Brain,2007

3. Myelin oligodendrocyte glycoprotein specific T and B-cells cooperate to induce a Devic-like disease in mice;Bettelli;J Clin Invest,2006

4. B-cells in multiple sclerosis;Duddy;Int MS J,2006

5. Distinct effector cytokine profiles of memory and naive human B-cell subsets and implication in multiple sclerosis;Duddy;J Immunol,2007

Cited by 643 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meningitis and intracranial abscess due to Mycoplasma pneumoniae in a B cell-depleted patient with multiple sclerosis;European Journal of Clinical Microbiology & Infectious Diseases;2024-09-13

2. Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-09-10

3. Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis;Frontiers in Immunology;2024-08-27

4. The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-08

5. Myelin-reactive B cells exacerbate CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner;Nature Communications;2024-06-26